BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 32564647)

  • 1. Development of a Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay for the Inhibition of Keap1-Nrf2 Protein-Protein Interaction.
    Lee S; Abed DA; Beamer LJ; Hu L
    SLAS Discov; 2021 Jan; 26(1):100-112. PubMed ID: 32564647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nuclear factor (erythroid-derived 2)-like 2 (NRF2) drug discovery: Biochemical toolbox to develop NRF2 activators by reversible binding of Kelch-like ECH-associated protein 1 (KEAP1).
    Bresciani A; Missineo A; Gallo M; Cerretani M; Fezzardi P; Tomei L; Cicero DO; Altamura S; Santoprete A; Ingenito R; Bianchi E; Pacifici R; Dominguez C; Munoz-Sanjuan I; Harper S; Toledo-Sherman L; Park LC
    Arch Biochem Biophys; 2017 Oct; 631():31-41. PubMed ID: 28801166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of fluorescently labeled Nrf2 peptide probes and the development of a fluorescence polarization assay for the discovery of inhibitors of Keap1-Nrf2 interaction.
    Inoyama D; Chen Y; Huang X; Beamer LJ; Kong AN; Hu L
    J Biomol Screen; 2012 Apr; 17(4):435-47. PubMed ID: 22156223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a High-Throughput Cul3-Keap1 Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay for Identifying Nrf2 Activators.
    Poore DD; Hofmann G; Wolfe LA; Qi H; Jiang M; Fischer M; Wu Z; Sweitzer TD; Chakravorty S; Donovan B; Li H
    SLAS Discov; 2019 Feb; 24(2):175-189. PubMed ID: 30383469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a steady-state FRET-based assay to identify inhibitors of the Keap1-Nrf2 protein-protein interaction.
    Schaap M; Hancock R; Wilderspin A; Wells G
    Protein Sci; 2013 Dec; 22(12):1812-9. PubMed ID: 24130096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measuring the Interaction of Transcription Factor Nrf2 with Its Negative Regulator Keap1 in Single Live Cells by an Improved FRET/FLIM Analysis.
    Dikovskaya D; Appleton PL; Bento-Pereira C; Dinkova-Kostova AT
    Chem Res Toxicol; 2019 Mar; 32(3):500-512. PubMed ID: 30793592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of novel inhibitors of Keap1/Nrf2 by a promising method combining protein-protein interaction-oriented library and machine learning.
    Shimizu Y; Yonezawa T; Sakamoto J; Furuya T; Osawa M; Ikeda K
    Sci Rep; 2021 Apr; 11(1):7420. PubMed ID: 33795749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimization of the C2 substituents on the 1,4-bis(arylsulfonamido)naphthalene-N,N'-diacetic acid scaffold for better inhibition of Keap1-Nrf2 protein-protein interaction.
    Abed DA; Ali AR; Lee S; Nguyen MU; Verzi MP; Hu L
    Eur J Med Chem; 2023 Apr; 252():115302. PubMed ID: 36989811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging Substrate Proteins of Kelch-like ECH Associated Protein 1 (Keap1) and Potential Challenges for the Development of Small-Molecule Inhibitors of the Keap1-Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Protein-Protein Interaction.
    Zhang Y; Shi Z; Zhou Y; Xiao Q; Wang H; Peng Y
    J Med Chem; 2020 Aug; 63(15):7986-8002. PubMed ID: 32233486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimization of 1,4-bis(arylsulfonamido)naphthalene-N,N'-diacetic acids as inhibitors of Keap1-Nrf2 protein-protein interaction to suppress neuroinflammation.
    Abed DA; Lee S; Wen X; Ali AR; Mangipudy V; Aleksunes LM; Hu L
    Bioorg Med Chem; 2021 Aug; 44():116300. PubMed ID: 34252790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent progress in Keap1-Nrf2 protein-protein interaction inhibitors.
    Mou Y; Wen S; Li YX; Gao XX; Zhang X; Jiang ZY
    Eur J Med Chem; 2020 Sep; 202():112532. PubMed ID: 32668381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protocol for a Steady-State FRET Assay in Cancer Chemoprevention.
    Schaap MC; Guimarães AM; Wilderspin AF; Wells G
    Methods Mol Biol; 2016; 1379():165-79. PubMed ID: 26608299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug screening assay based on the interaction of intact Keap1 and Nrf2 proteins in cancer cells.
    Zhou B; Zhang X; Wang G; Barbour KW; Berger FG; Wang Q
    Bioorg Med Chem; 2019 Jan; 27(1):92-99. PubMed ID: 30473361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-activity relationships of 1,4-bis(arylsulfonamido)-benzene or naphthalene-N,N'-diacetic acids with varying C2-substituents as inhibitors of Keap1-Nrf2 protein-protein interaction.
    Lee S; Abed DA; Nguyen MU; Verzi MP; Hu L
    Eur J Med Chem; 2022 Jul; 237():114380. PubMed ID: 35462166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction Energetics and Druggability of the Protein-Protein Interaction between Kelch-like ECH-Associated Protein 1 (KEAP1) and Nuclear Factor Erythroid 2 Like 2 (Nrf2).
    Zhong M; Lynch A; Muellers SN; Jehle S; Luo L; Hall DR; Iwase R; Carolan JP; Egbert M; Wakefield A; Streu K; Harvey CM; Ortet PC; Kozakov D; Vajda S; Allen KN; Whitty A
    Biochemistry; 2020 Feb; 59(4):563-581. PubMed ID: 31851823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of Noncovalent Small-Molecule Keap1-Nrf2 Inhibitors by Fragment-Based Drug Discovery.
    Narayanan D; Tran KT; Pallesen JS; Solbak SMØ; Qin Y; Mukminova E; Luchini M; Vasilyeva KO; González Chichón D; Goutsiou G; Poulsen C; Haapanen N; Popowicz GM; Sattler M; Olagnier D; Gajhede M; Bach A
    J Med Chem; 2022 Nov; 65(21):14481-14526. PubMed ID: 36263945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peptide and small molecule inhibitors of the Keap1-Nrf2 protein-protein interaction.
    Wells G
    Biochem Soc Trans; 2015 Aug; 43(4):674-9. PubMed ID: 26551711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoacidic Inhibitors of the Kelch-like ECH-Associated Protein 1: Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1:NRF2) Protein-Protein Interaction with High Cell Potency Identified by Fragment-Based Discovery.
    Davies TG; Wixted WE; Coyle JE; Griffiths-Jones C; Hearn K; McMenamin R; Norton D; Rich SJ; Richardson C; Saxty G; Willems HM; Woolford AJ; Cottom JE; Kou JP; Yonchuk JG; Feldser HG; Sanchez Y; Foley JP; Bolognese BJ; Logan G; Podolin PL; Yan H; Callahan JF; Heightman TD; Kerns JK
    J Med Chem; 2016 Apr; 59(8):3991-4006. PubMed ID: 27031670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and Development of Kelch-like ECH-Associated Protein 1. Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1:NRF2) Protein-Protein Interaction Inhibitors: Achievements, Challenges, and Future Directions.
    Jiang ZY; Lu MC; You QD
    J Med Chem; 2016 Dec; 59(24):10837-10858. PubMed ID: 27690435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systematic molecular dynamics approach to the study of peptide Keap1-Nrf2 protein-protein interaction inhibitors and its application to p62 peptides.
    Lu MC; Yuan ZW; Jiang YL; Chen ZY; You QD; Jiang ZY
    Mol Biosyst; 2016 Apr; 12(4):1378-87. PubMed ID: 26935067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.